The FDA has approved Zepbound, a weight-loss drug, as the first pharmacologic therapy to treat obstructive sleep apnea. In a trial conducted by Lilly, scientists found that Zepbound helped people who were overweight or obese with sleep apnea reduce breathing restrictions by 63% and experience fewer interrupted sleep events by 30%. The new indication applies to individuals with specific type of sleep apnea caused by excess fat tissue in the throat, which can block air passages. By treating obesity, Zepbound reduces obstruction, allowing for better airflow. This approval is expected to help doctors and patients effectively treat both conditions, particularly those already taking Zepbound. Additionally, studies have shown that the drug can also reduce the progression of heart failure and kidney disease.
Source: https://time.com/7203597/zepbound-sleep-apnea-fda